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Background:  Treatment of breast cancer with trastuzumab, a new monoclonal antibody, may be complicated by cardiac dysfunction in up to 
28% of cases. In most patients, trastuzumab-induced cardiotoxicity (TIC) seems to be reversible, and left ventricular ejection fraction (LVEF) usually 
improves after trastuzumab withdrawal and initiation of heart failure (HF) therapy. The reversibility of TIC, however, is not foreseeable, so that the 
identification of patients at high-risk from TIC, and those who will not recover from it is crucial. The role of Troponin I (TNI) in this setting has never 
been investigated.
Methods:  All consecutive women treated with trastuzumab at our centre, from 2002 to 2008, were considered. Troponin concentration was 
measured before and soon after each trastuzumab cycle. LVEF was evaluated at baseline, every 3 months during trastuzumab therapy (mean 
duration 17±15 months), and every 6 months after the end of treatment (mean follow-up19±14 months). In case of TIC, trastuzumab was 
discontinued and treatment with enalapril and carvedilol was initiated. We considered the following end-points: 1) incidence of TIC (decrease in LVEF 
>10 units, associated with a decline below its normal limit of 50%); 2) recovery from TIC (LVEF increase up to 50%).
Results:  Two-hundred-forty-six women were enrolled (mean age 50±10 years). TIC occurred in 42 patients (17%). Troponin increased was observed 
in 36 cases (14%). Trastuzumab-induced cardiotoxicity occurred more frequently in patients with TNI increase than in those without TNI increase 
(62% vs. 5%; p<0.001). Twenty-five (60%) of patients recovered from TIC; patients not recovering from TIC showed a higher percentage of TNI 
positivity than whose who recovered (100% vs. 36%; p<0.001). At multivariate analysis, adjusted for age, cardiovascular risk factors, baseline LVEF, 
TNI positivity was the only independent predictor of TIC (HR 16.2; 95% CI, 8.3-31.7; p<0.0001). In patients with TIC, the HR for no recovery in TNI 
positive patients was 2.9 (CI 95%, 1.7-3.9; p<0.001).
Conclusions:  In trastuzumab-treated patients, TNI measurement is an useful tool to identify patients at risk of TIC and of not recover from cardiac 
dysfunction. 
